Laboratory and Clinical Assessment of Insulin Resistance

Primary Screening Laboratory Tests

• Fasting plasma glucose (FPG) should be used as the initial screening test because it is easy, inexpensive, and widely available in office settings 1.
• An FPG value of 100–125 mg/dL defines impaired fasting glucose (IFG), indicating insulin resistance and pre‑diabetes 2.
• FPG measurement requires a minimum 8‑hour fast without any caloric intake 2.
• A normal FPG does not rule out insulin resistance, as glucose abnormalities often appear later in the disease course 1.

Fasting Insulin Assessment

• Fasting plasma insulin directly measures hyperinsulinemia and serves as a marker of insulin resistance 1.
• Interpretation thresholds for fasting insulin:
  
  • Normal < 15 mU/L
  • Borderline 15–20 mU/L
  • High > 20 mU/L (suggestive of insulin resistance)  1.

Confirmatory Laboratory Tests

• Oral glucose tolerance test (OGTT) is performed with a 75 g glucose load after an overnight fast [2][3].
• A 2‑hour OGTT plasma glucose of 140–199 mg/dL defines impaired glucose tolerance (IGT), reflecting insulin resistance 2.
• Hemoglobin A1C values of 5.7–6.4 % indicate pre‑diabetes with underlying insulin resistance 2.
• A lipid panel should be ordered as part of a comprehensive metabolic assessment 1.

Physical Examination Findings Indicative of Insulin Resistance

• Acanthosis nigricans (hyperpigmented, velvety skin in body folds) is a direct clinical sign of insulin resistance [1][4]2.
• Central/abdominal obesity with increased waist circumference is associated with insulin resistance [1][4].
• Elevated blood pressure (hypertension) correlates with insulin resistance [1][4]2.

Risk Factors that Prompt Testing

• Body‑mass index ≥ 25 kg/m² (or ≥ 23 kg/m² for Asian‑American individuals) warrants evaluation for insulin resistance 2.
• A first‑degree family history of type 2 diabetes is a risk factor 2.
• High‑risk racial/ethnic groups (American Indian, African American, Hispanic, Asian/Pacific Islander) should be screened 2.
• History of gestational diabetes or delivery of an infant > 9 lb is a risk factor 3.
• Hypertension (≥ 140/90 mmHg) is an indication for testing 3.
• Physical inactivity increases the need for assessment 3.

Testing Conditions and Limitations

• All glucose‑related tests must be performed after a true fasting state (≥ 8 hours without caloric intake) to avoid post‑prandial variability [2][3].
• Medications that affect glucose metabolism (e.g., corticosteroids, atypical antipsychotics) should be considered when interpreting results 2.
• The euglycemic insulin clamp remains the gold‑standard method for measuring insulin sensitivity, but its requirement for a 3‑hour intravenous infusion makes it impractical for routine clinical use (research‑only tool) [1][4].

Special Populations

• In children and adolescents, testing should begin after the onset of puberty or at age 10 years (whichever occurs first) 2.
• Testing in youth requires overweight/obesity (≥ 85th percentile) plus additional risk factors 2.
• Repeat testing every 3 years is recommended if initial results are normal; more frequent testing is advised if BMI is rising 2.

Frequency of Repeat Testing in Adults

• If initial screening tests are normal, repeat evaluation at a minimum interval of 3 years [2][3].
• Testing should be performed more frequently when BMI is increasing or when the overall risk‑factor profile deteriorates 2.

Diagnosing Insulin Resistance

Risk Assessment for Insulin Resistance

• The American Heart Association suggests that overweight or obesity (BMI ≥25 kg/m² or ≥23 kg/m² in Asian Americans) is a risk factor for insulin resistance 5, 6
• The American College of Cardiology recommends considering family history of type 2 diabetes as a risk factor for insulin resistance 7, 8
• Racial/ethnic predisposition (American Indian, African American, Hispanic, or Asian/Pacific Islander) is a risk factor for insulin resistance, according to the American Heart Association 7, 8
• Physical signs of insulin resistance, including acanthosis nigricans, hypertension, dyslipidemia, or polycystic ovary syndrome, should be considered as risk factors, as suggested by the American College of Cardiology 7, 8, 9

Diagnostic Tests for Insulin Resistance

• Fasting plasma glucose (FPG) values between 100-125 mg/dL indicate impaired fasting glucose, suggesting insulin resistance, as recommended by the American Diabetes Association 5
• Fasting plasma insulin levels, with normal <15 mU/L, borderline high 15-20 mU/L, and high >20 mU/L, can be used to diagnose insulin resistance, according to the American College of Cardiology 7, 8
• The American Diabetes Association recommends using the oral glucose tolerance test (OGTT) with 2-hour glucose values of 140-199 mg/dL to indicate impaired glucose tolerance, suggesting insulin resistance 5
• Hemoglobin A1C values between 5.7-6.4% suggest prediabetes and potential insulin resistance, as recommended by the American Diabetes Association 5

Clinical Evaluation

• A comprehensive clinical evaluation should include a physical examination to look for acanthosis nigricans, central obesity, and signs of associated conditions, as suggested by the American College of Cardiology 7, 8, 9
• Laboratory assessment should include checking lipid profile and blood pressure, according to the American College of Cardiology 7, 8, 9

Interpreting Results

• The presence of impaired fasting glucose (100-125 mg/dL) or impaired glucose tolerance (2-hour OGTT 140-199 mg/dL) indicates prediabetes and likely insulin resistance, as recommended by the American Diabetes Association 5
• Elevated fasting insulin levels (>15 mU/L) directly suggest insulin resistance, according to the American College of Cardiology 7, 8

Special Considerations

• Measuring C-peptide alongside insulin can help differentiate between endogenous insulin production and exogenous insulin administration, as suggested by the American Association of Clinical Endocrinologists 10
• Simultaneous elevation of insulin and C-peptide suggests endogenous hyperinsulinism, which may indicate insulin resistance, according to the American Association of Clinical Endocrinologists 10

Common Pitfalls and Caveats

• Insulin resistance testing should be performed in the fasting state to avoid postprandial variations, as recommended by the American College of Cardiology 7, 8
• Medications that affect glucose metabolism should be noted when interpreting results, according to the American Society of Anesthesiologists 11
• Stress hyperglycemia during acute illness can temporarily mimic insulin resistance and should not be used for diagnosis, as suggested by the American Society of Anesthesiologists 11
• Isolated elevated C-peptide without hypoglycemia generally reflects insulin resistance rather than pathological hyperinsulinism, according to the American Association of Clinical Endocrinologists 10

Diagnostic Thresholds and Evaluation for Insulin Resistance

Diagnostic Criteria

• Fasting insulin > 10 mIU/L is used as a diagnostic threshold for insulin resistance in clinical trials of polycystic ovary syndrome (PCOS). This cutoff identifies individuals with early metabolic dysfunction and is supported by trial data published in Obesity Reviews (2024) 12.

• An oral glucose tolerance test (OGTT) 2‑hour glucose value of 140–199 mg/dL defines impaired glucose tolerance (IGT), a state that reflects underlying insulin resistance. The definition is based on criteria endorsed in the European Heart Journal (2013) 13.

Laboratory and Testing Recommendations

• All glucose‑related tests (fasting plasma glucose, OGTT, HbA1c) must be performed after a true fasting period of ≥ 8 hours to avoid post‑prandial variability. This procedural requirement is emphasized in Diabetes Care (2023) 14.

Management Recommendations

• Lifestyle modification is the cornerstone of therapy for insulin resistance and prediabetes. Recommended interventions include a balanced diet (≈ 50 % carbohydrate, 20 % protein, 30 % fat with increased fiber) and at least 30 minutes of moderate‑intensity physical activity daily. Evidence from the 2024 Obesity Reviews article supports this approach as effective in improving insulin sensitivity 12.

Special Considerations for Women of Reproductive Age

• Screening for PCOS should be considered when fasting insulin exceeds 10 mIU/L, because insulin resistance is a central pathophysiologic feature of PCOS and the same cutoff has been applied in PCOS trial protocols (Obesity Reviews 2024) 12.